Hemolytic Uremic Syndrome 8.13.18

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 34

Morning Report 8/13/18

TED TANNER, MD MPH


Chief Complaint: “Blood in stool”

 4-year-old female with 4 days of diarrhea, 1 day of


tactile fever, and 1 day of bloody diarrhea
 Patient became suddenly ill 4 days ago
 Diarrhea accompanied by crampy abdominal pain,
poor appetite, and 1 episode of non-bloody/non-
bilious emesis
 Abdominal pain is generalized and intermittent
 Mom says the bloody diarrhea fills the toilet
 Seen at urgent care this morning, and referred to our
ED for further evaluation
History Continued

 History of constipation. She usually has one hard


stool every other day for the last year. She does not
take any medications for this.
 No known sick contacts
 No one home with similar symptoms
 Denies urinary symptoms, rash, weight loss, lethargy
History Continued

 No significant past medical history other than


constipation
 No medication
 No allergies
 UTD on immunizations
 No family history of IBD, or other chronic medical
problems
 Lives with parents, 3 siblings, aunt, and 2 uncles
 Attends pre-school. Active child who likes to play outside
 No recent travel, no contact with open water sources
Physical Exam

 T 36.6, HR 93, RR 20, BP 98/58, Wt 25.5, BMI 17.13


 Gen: alert, interactive, non-toxic
 HEENT: normal
 Resp: CTAB
 CV: RRR, no murmurs, normal cap refill
 GI: abdomen soft, mild periumbilical tenderness, non-
distended, no organomegaly, negative heel-tap
 GU: approx 2mm anal fissure at 7 o’clock, 1 mm fissure at
8 o’clock
 Skin: no rashes
 MSK: no joint swelling
 Neuro: normal mental status, CN intact, strength normal
CC: “Blood in Stool”

DDX.
WORK-UP
Differential Dx.
Labs
CC: “Blood in stool”

 E. Coli infectious colitis


 Anal fissure
 IV bolus x2 in the ED, drinking slushies, without
complaint on re-examination
 Discharge home from ED with PCP follow-up, return
precautions
Returns to ED the next day

 Diarrhea has not improved


 Continues to have blood in stool
 DOI 5, now 2 days of frank, bloody stool
 Now having 20+ stools/day
 Poor oral intake, poor urine output
 Afebrile, HR 116, BP 107/75, wt 25.6
 Lips chapped, rest of exam the same
Labs

 WBC 9.7 > 12.8  Na 139 > 139


 Hgb 14.1 > 15.2  K 3.8 > 3.9
 Hct 40.5 > 42.4  Cl 108 > 108
 Plts 244 > 200  CO2 19 > 16
 BUN 10 > 9
 Cr 0.47 > 0.57
CC: Persistent bloody stool

 Dehydrated: received 20cc/kg NS bolus, drinking in


the ED, perked up and was feeling well
 Dx: E. Coli infectious colitis, diarrhea
 DC home, PCP follow-up, return precautions
She returns 2 days later!

 Diarrhea has actually improved, but still having


abdominal pain
 No more blood in the stool
 24h of severe, crampy, periumbilical abdominal pain
 Poor appetite
 No fevers, no pain with coughing, no pain with
walking, no emesis
Afebrile
HR 134
BP 104/65
(95th %tile 112/71)
Wt. 25.3

CC: abdominal pain


Labs
Labs
Labs

Plts: 244 > 200 > 32


Hgb: 14.1 > 15.2 > 10.0
Cr: 0.47 > 0.57 > 1.73
• E. Coli colitis
• Anemia
Diagnosis? • Thrombocytopenia
• Acute kidney failure
• Petechiae
Hemolytic Uremic Syndrome

 Classic triad of microangiopathic hemolytic anemia,


thrombocytopenia, and acute kidney injury
 One of the main causes of acute kidney injury in
children
 Shiga toxin-producing E. Coli HUS is the most
common cause of pediatric HUS, 90% of cases
 2-3 per 100,000 children less than 5 years of age
 Primary HUS: diarrhea-negative
 Secondary HUS: diarrhea-positive, infection-induced
Primary HUS

 Complement-mediated: mutations in genes for C3


and CD46
 Coagulation pathway
 Diacylglycerol kinase epsilon (DGKE) mutation- complement
activation with low C3 levels
 PLG mutation- plasminogen deficiency
 Thrombomodulin mutations – cofactor in Protein C pathway
 Methylmalonic Aciduria and Homocystinuria type C
 B12 deficiency
Infection-Induced Secondary HUS

 Strep pneumoniae: 5% of all childhood HUS cases


 Infants and young children
 Incidence of HUS after pneumococcal disease is 0.5%
 70% present with pneumonia
 More severe initial with longer duration of oliguria and
thrombocytopenia
 In two separate case series, 70-80% underwent dialysis
 10% progress to ESRD
 HIV infection
 H1N1 Infleunza A: strep pneumo common secondary
infection
 Shigella: 15% mortality, 40% CKD. India, Bangladesh,
Southern Africa
Shiga toxin-producing E. coli HUS

CONNECT TO
UPTODATE FOR MORE INFORMATION
STEC-HUS

 Microangiopathic hemolytic anemia: shearing of


RBCs through platelet microthrombi
 Hgb <8, Negative Coombs’, Smear with schistocytes and
helmet cells
STEC-HUS

 Thrombocytopenia: platelet count < 140,000


 Usually no purpura or active bleeding
 Degree is unrelated to renal dysfunction
STEC-HUS

 Acute kidney injury: renal involvement ranges from


hematuria and proteinuria to severe AKI and
oligoanuria
 Severe AKI in 50% of cases, but recovery is favorable even in
those who require dialysis
STEC-HUS other organ involvement

 CNS: seizures, coma, stroke, cortical blindness (20%


of cases due to E. coli 0157:H7)
 GI: severe hemorrhagic colitis, bowel necrosis, rectal
prolapse, peritonitis
 CV: cardiac dysfunction due to fluid overload,
hypertension, hyperkalemia, thrombotic
microangiopathy, myocarditis, tamponade
 Pancreas: glucose intolerance, transient DM
 Liver: hepatomegaly and transaminitis
 Hematology: leukocytosis, prognosis is worse with
elevated WBCs
Post-diarrhoeal
HUS
Shiga toxins (Stx) target
Gb3-rich tubular
epithelium and
glomerular endothelial
cells which leads to
apoptosis, necrosis, and
thrombotic
microangiopathy.
Evaluation and Diagnosis

 A patient with recent bloody diarrhea with signs of


other organ involvement (oliguria, AMS, anemia,
etc.) deserves evaluation for HUS
 CBC, renal function studies, GIPCR
 Diagnosis is clinical: symptoms + triad of lab
findings. Renal bx not required
 Differential: DIC, TTP, other infections leading to
volume depletion and subsequently renal injury
Management

 Prevention: avoiding undercooked meats


 No benefit from antibiotics or antimotility agents

 Vigorous fluid resuscitation


 Use of IVF up to the day of HUS diagnosis associated with
decreased use of RRT
 Mortality increased for dehydrated patients (OR 3.71)

 Closely monitor renal function and blood counts


Antibiotic and Antimotility Agents

 Increase the risk of subsequent development of


STEC-HUS
 Increased risk of HUS during bloody diarrhea phase
 Do not decrease duration of diarrheal symptoms
 One study found that the use of anticholinergic agents and
narcotics increased risk of CNS dysfunction
Supportive Therapy

 PRBCs for Hgb <6 or Hct <18, with goal of Hgb 8-9
 Platelet transfusion if bleeding or before procedure
 Fluid management
 Depletion from vomiting, diarrhea, poor intake
 Overload from oliguria or anuria
 Closely monitor for signs of fluid overload: HTN, cardiopulmonary
overload.
 Ok to trial loop diuretics, but should these fail, move to CRRT

 Electrolyte management
 Hypertension: fix fluid status, CCBs, switch to ACEi
once AKI resolves
Indications for Dialysis

 Signs and symptoms of uremia (encephalitis, acidosis)


 Azotemia: BUN >/= 80-100 mg/dL
 Severe fluid overload (cardiopulmonary compromise)
 Severe electrolyte abnormalities (hyperkalemia)
 Need for nutritional support
Specific Therapies

 Eculizumab, mab to C5 that blocks complement


activation
 Used in patients with STEC-HUS with severe CNS involvement
or other severe organ involvement
 Mostly used for complement mediated HUS
 Must be given early to see benefit
 No strong evidence to support antithrombotic agents
or oral shiga toxin-binding agents
Prognosis

 Hematologic manifestations resolve in 1-2 weeks,


followed by kidney recovery
 Mortality rate <5%
 Acutely due to: CNS injury, coagulopathy, sepsis, heart failure
 Long-term: 60-70% recover completely from acute
phase
 Renal outcome: hypertension, proteinuria, CKD
 Follow-up yearly for 5 years

You might also like